Modulation of Glucagon Signaling: A Metabolic Approach for Heart Failure?

Overview

Journal JACC Basic Transl Sci

Date 2019 May 8

PMID 31061919

Citations 2

Authors

Alessandro Pocai

Affiliations

Soon will be listed here.

Citing Articles

Emerging Anti-Diabetic Drugs for Beta-Cell Protection in Type 1 Diabetes.

Ajmal N, Bogart M, Khan P, Max-Harry I, Nunemaker C Cells. 2023; 12(11).

PMID: 37296593 PMC: 10253164. DOI: 10.3390/cells12111472.

Common differentially expressed genes and pathways correlating both coronary artery disease and atrial fibrillation.

Zheng Y, He J EXCLI J. 2021; 20:126-141.

PMID: 33564282 PMC: 7868642. DOI: 10.17179/excli2020-3262.

References

Horton J, Davidson M, Kurishima C, Vega R, Powers J, Matsuura T . The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense. JCI Insight. 2019; 4(4). PMC: 6478419. DOI: 10.1172/jci.insight.124079. View

Myers R, Guan H, Ehrhart J, Petrov A, Prahalada S, Tozzo E . Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy. Science. 2017; 357(6350):507-511. DOI: 10.1126/science.aah5582. View

Hollander P, Bays H, Rosenstock J, Frustaci M, Fung A, Vercruysse F . Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial. Diabetes Care. 2017; 40(5):632-639. DOI: 10.2337/dc16-2427. View

Sharma A, Quittner-Strom E, Lee Y, Johnson J, Martin S, Yu X . Glucagon Receptor Antagonism Improves Glucose Metabolism and Cardiac Function by Promoting AMP-Mediated Protein Kinase in Diabetic Mice. Cell Rep. 2018; 22(7):1760-1773. PMC: 5978750. DOI: 10.1016/j.celrep.2018.01.065. View

Saponaro C, Pattou F, Bonner C . SGLT2 inhibition and glucagon secretion in humans. Diabetes Metab. 2018; 44(5):383-385. DOI: 10.1016/j.diabet.2018.06.005. View

Bergman A, Tan B, Somayaji V, Calle R, Kazierad D . A 4-week study assessing the pharmacokinetics, pharmacodynamics, safety, and tolerability of the glucagon receptor antagonist PF-06291874 administered as monotherapy in subjects with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2017; 126:95-104. DOI: 10.1016/j.diabres.2017.01.019. View

Guzman C, Zhang X, Liu R, Regev A, Shankar S, Garhyan P . Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes. Diabetes Obes Metab. 2017; 19(11):1521-1528. DOI: 10.1111/dom.12958. View

Pettus J, Reeds D, Cavaiola T, Boeder S, Levin M, Tobin G . Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial. Diabetes Obes Metab. 2017; 20(5):1302-1305. PMC: 6181222. DOI: 10.1111/dom.13202. View

Sinha B, Ghosal S . Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. Diabetes Res Clin Pract. 2019; 150:8-16. DOI: 10.1016/j.diabres.2019.02.014. View

10.

Zhou C, Dhall D, Nissen N, Chen C, Yu R . Homozygous P86S mutation of the human glucagon receptor is associated with hyperglucagonemia, alpha cell hyperplasia, and islet cell tumor. Pancreas. 2009; 38(8):941-6. PMC: 2767399. DOI: 10.1097/MPA.0b013e3181b2bb03. View

11.

Clemmensen C, Finan B, Muller T, DiMarchi R, Tschop M, Hofmann S . Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases. Nat Rev Endocrinol. 2018; 15(2):90-104. DOI: 10.1038/s41574-018-0118-x. View

12.

Petersen K, Bogevig S, Holst J, Knop F, Christensen M . Hemodynamic Effects of Glucagon: A Literature Review. J Clin Endocrinol Metab. 2018; 103(5):1804-1812. DOI: 10.1210/jc.2018-00050. View

13.

Ali S, Ussher J, Baggio L, Kabir M, Charron M, Ilkayeva O . Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction. Mol Metab. 2015; 4(2):132-43. PMC: 4314543. DOI: 10.1016/j.molmet.2014.11.005. View

14.

Gasbjerg L, Gabe M, Hartmann B, Christensen M, Knop F, Holst J . Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents. Peptides. 2018; 100:173-181. DOI: 10.1016/j.peptides.2017.11.021. View

15.

Muller T, Finan B, Clemmensen C, DiMarchi R, Tschop M . The New Biology and Pharmacology of Glucagon. Physiol Rev. 2017; 97(2):721-766. DOI: 10.1152/physrev.00025.2016. View

16.

Ali S, Drucker D . Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes. Am J Physiol Endocrinol Metab. 2009; 296(3):E415-21. DOI: 10.1152/ajpendo.90887.2008. View

17.

Gao C, Ren S, Yu J, Baal U, Thai D, Lu J . Glucagon Receptor Antagonism Ameliorates Progression of Heart Failure. JACC Basic Transl Sci. 2019; 4(2):161-172. PMC: 6488764. DOI: 10.1016/j.jacbts.2018.11.001. View

18.

Larger E, Wewer Albrechtsen N, Hansen L, Gelling R, Capeau J, Deacon C . Pancreatic α-cell hyperplasia and hyperglucagonemia due to a glucagon receptor splice mutation. Endocrinol Diabetes Metab Case Rep. 2016; 2016. PMC: 5118975. DOI: 10.1530/EDM-16-0081. View